Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 4, 2015, Pages 475-480

  Chu, N H ^a   Li, L ^b   Zhang, X ^c   Gu, J ^d   Du, Y D ^a   Cai, C ^a   Xiao, H P ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Tianjin Haihe Hospital   (China)

^c NANJING CHEST HOSPITAL   (China)

^d SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Liver protecting; Normal healthy HBV carrier; Pure steatosis

Indexed keywords

BICYCLOL; ETHAMBUTOL; GLUCURONOLACTONE; ISONIAZID; LIVER PROTECTIVE AGENT; PYRAZINAMIDE; RIFAMPICIN; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INCIDENCE; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SURVIVAL; TOXIC HEPATITIS; TUBERCULOSIS; ADOLESCENT; CHINA; CLINICAL TRIAL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; FATTY LIVER; HEPATITIS B; LIVER; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BIPHENYL COMPOUNDS; CHINA; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FEMALE; HEPATITIS B; HUMANS; LIVER; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84925669809     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0579     Document Type: Article

References (35)

1. Chen C W. Pathogenesis and treatment strategies of druginduced liver injury. Zhonghua Jie He He Hu Xi Za Zhi 2013; 36: 726-728.
2. Agal S, Baijal R, Pramanik S, et al. Monitoring and management of anti-tuberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005; 20: 1745-1752.
3. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
4. Xia Y Y, Zhan S Y. Systematic review of anti-tuberculosis druginduced adverse reactions in China. Zhonghua Jie He He Hu Xi Za Zhi 2007; 30: 419-423.
5. Chen Y K, Yan X F. Anti-tuberculosis therapy in patients with liver diseases and tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2013; 36: 769-771.
6. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-6557.
7. Fan J G. Epidemiology of alcoholic and non-alcoholic fatty liver disease in China. J Gastroenterol Hepatol 2013; 28 (Suppl 1): S11-S17.
8. Xiao H P. Debate on the prophylactic application of hepatoprotectants during anti-tuberculosis treatment. Zhonghua Jie He He Hu Xi Za Zhi 2013; 36: 722-723.
9. Liu G T, Li Y, Wei HL, Zhang H, Xu J Y, Yu L H. Mechanism of protective action of bicyclol against CCl-induced liver injury in mice. Liver Int 2005; 25: 872-879.
10. Wang H, Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol 2006; 534: 194-201.
11. Pan S Y, Dong H, Yu Z L, et al. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol 2007; 59: 1657-1662.
12. Xie W, Shi G, Zhang H, et al. A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int 2012; 6: 441-448.
13. Han Y, Shi J-P, Ma A-L, Xu Y, Ding X-D, Fan J-G. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clinical Drug Investigation 2014; 34: 1-7.
14. Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res 2014; 42: 906-914.
15. Ministry of Health of the People's Republic of China. Diagnostic criteria for pulmonary tuberculosis. WS 288-2008. In: People's Republic of China Sanitary Industry Standard. Beijing, China: MoH, 2008.
16. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
17. Zeng M D, Fan J G, Lu L G, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008; 9: 108-112.
18. Donglou X, Ma Y, Zhu L-Z. Clinical manifestations of antituberculosis drugs' adverse reactions. In: Diagnosis and treatment manual for adverse reactions of anti-tuberculosis drugs. Beijing, China: People's Health Publishing House, 2009: pp 15.
19. Kumar R, Shalimar, Bhatia V, et al. Anti-tuberculosis therapyinduced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010; 51: 1665-1674.
20. Chang K C, Leung C C, Yew W W, Lau T Y, Tam C M. Hepatotoxicily of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177: 1391-1396.
21. Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLOS ONE 2011; 6: e21836.
22. Li S, Hu Z H, Miao X H. Effects of chronic HBV infection on human hepatic cytochrome P450 3A4. Zhonghua Yi Xue Za Zhi 2006; 86: 2703-2706.
23. Lee B H, Koh W J, Choi M S, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127: 1304-1311.
24. Wong W-M, Wu P-C, Yuen M-F, et al. Anti-tuberculosis drugrelated liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
25. Tarantino G, Conca P, Basile V, et al. A prospective research of acute drug-induced liver injury in patients suffering from nonalcoholic fatty liver disease. Hepatol Res 2007; 37: 410-415.
26. Powell E E, Jonsson J R, Clouston A D. Steatosis: co-factor in other liver disease. Hepatology 2005; 42: 5-13.
27. Shi Z-M. Effects of anti-tuberculosis drugs combined with glucuronolactone on liver function in tuberculosis patients. Intern Med 2011; 6: 443-444.
28. Yu Y-N, Chen H, Li Y. Effect of bicyclol on cisplatin-Induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice. Basic Clin Pharmacol Toxicol 2009; 104: 300-305.
29. Yao X-M, Chen H, Yan L. Protective effect of bicyclol on liver injury induced by hepatic warm ischemia/reperfusion in rats. Hepatol Res 2009; 39: 833-842.
30. Lou X-E, Xu N, Yao H-P, Chen Z. Bicyclol attenuates proinflammatory cytokine and chemokine productions in CpGDNA-stimulated L02 hepatocytes by inhibiting p65-NF-jB and p38-MAPK activation. Pharmazie 2010; 65: 206-212.
31. Bao X-Q, Liu G-T. Involvement of HSP70 in the protection of bicyclol on apoptosis of HepG2 cells intoxicated by Dgalactosamine. J Asian Natural Products Res 2010; 12: 313-323.
32. Zhao D, Liu G. Protective effect of bicyclol on concanavalin Ainduced liver nuclear DNA injury in mice. Zhonghua Yi Xue Za Zhi 2001; 81: 844-848.
33. Yu H-Y, Wang B-L, Zhao J, et al. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology 2009; 261: 112-118.
34. Liu G-T. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem 2009; 5: 29-43.
35. Huang S-P, Wu D, et al. Effect of bicyclol on pharmacokinetics of rifampin and isoniazid in rats. Tianjin Pharmacy 2010; 22: 4-7.